ClinicalTrials.gg
Active, not recruitingNCT06154837Updated Nov 6, 2026

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

A Phase 1 interventional study of GSK3862995B and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Active, not recruiting at 31 sites in 3 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Updated Nov 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Enrollment
112th of 236
127 · median 101
Started
2023
with 2 others
Phase 1
83 of 276
1 open now
Registered
266th of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 112th largest by enrollment of the 236 interventional ones that give a count, is one of 3 that started in 2023, is one of 83 in phase 1, and was the 266th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • GSK3862995B
  • Chronic Obstructive Pulmonary Disease
  • Phase 1
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy participants (Part A)

  • Participant must be 18 to 65 years of age inclusive.
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
  • Body weight within the range 50-110 kilogram (kg) (inclusive)
  • (BMI) within the range 19.5-32 kilogram per square meter (kg/m\^2)
  • Male and/or female of non-

Participants with Chronic Obstructive Pulmonary Disorder () (Part B)

  • Participant must be 40 to 75 years of age inclusive.
  • Body weight within the range 50-110 kg (inclusive)
  • BMI within the range 19.5-32 kg/m\^2
  • Participant has a confirmed diagnosis of COPD for greater than (>)12 months
  • Participants must present with a measured post-salbutamol /Forced vital capacity (FEV1/FVC) ratio of less than (\<) 0.70 at screening to confirm the diagnosis of COPD and a measured post-salbutamol FEV1 greater than or equal to (>=) 40% of predicted normal values.
  • Participants must have a well-documented requirement for optimized standard of care background therapy that includes daily inhaled medication.
  • A peripheral blood eosinophil count of >=150 cells/microliter (mcL) at screening
  • Former cigarette smokers with a history of cigarette smoking of >=10 pack-years at screening current smokers (includes the use of any type of nicotine containing product), or non-smokers are permitted
  • Male and/or female of non-childbearing potential.

Exclusion criteria

Exclusion Criteria:

  • Participant has a past or current medical condition(s) or disease(s) that is/are not well controlled and, which in the judgement of the Investigator, may affect participant safety or affect study endpoints.
  • A history of recurrent infections, or treatment of a chronic infection within 3 months prior to the first dose of study drug, including both serious local infection (for example, cellulitis, abscess) or systemic infection (for example, pneumonia, tuberculosis, , shingles).
  • Significant allergies to humanized monoclonal antibodies.
  • multiple or severe drug allergies, intolerance to topical , or severe post-treatment reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
  • Lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Breast cancer within the past 10 years
  • (ALT) >1x (ULN)
  • Total >1.5xULN (isolated total bilirubin >1.5xULN is acceptable if total bilirubin is fractionated and direct bilirubin less than (\<) 35%).
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • A clinically significant abnormality in 12-lead readings performed at screening
  • A clinically significant abnormality in the Holter monitor performed at screening (IV cohorts only).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Part A Dose Level 1: Single dose of GSK3862995B

    Healthy participants will receive single dose of GSK3862995B.

    Drug: GSK3862995B

  • Experimental
    Part A Dose Level 2: Single dose of GSK3862995B

    Healthy participants will receive single dose of GSK3862995B.

    Drug: GSK3862995B

  • Experimental
    Part A Dose Level 3: Single dose of GSK3862995B

    Healthy participants will receive single dose of GSK3862995B.

    Drug: GSK3862995B

  • Experimental
    Part A Dose Level 4: Single dose of GSK3862995B

    Healthy participants will receive single dose of GSK3862995B.

    Drug: GSK3862995B

  • Experimental
    Part A Dose Level 5: Single dose of GSK3862995B

    Healthy participants will receive single dose of GSK3862995B.

    Drug: GSK3862995B

  • Experimental
    Part A Dose Level 6: Single dose of GSK3862995B

    Healthy participants will receive single dose of GSK3862995B.

    Drug: GSK3862995B

  • Placebo comparator
    Part A: Placebo

    Healthy participants will receive single dose of placebo.

    Drug: Placebo

  • Experimental
    Part B: Repeat dose of GSK3862995B

    Participants with COPD will receive repeat doses of GSK3862995B.

    Drug: GSK3862995B

  • Placebo comparator
    Part B: Placebo

    Participants with COPD will receive repeat doses of placebo.

    Drug: Placebo

Interventions

  • GSK3862995B will be administered.

  • DrugPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.

    Time frame: Up to 36 weeks

  2. Part B: Number of Participants with AEs and SAEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.

    Time frame: Up to 48 weeks

  3. Part A: Number of Participants with Clinically significant changes in laboratory values

    Number of Participants with clinically significant changes in laboratory values (haematology, chemistry, and urinalysis) will be assessed.

    Time frame: Up to 28 weeks

  4. Part A: Number of Participants with Clinically Significant Change in vital signs

    Number of participants with clinically significant change in vital signs (tympanic temperature, pulse rate, respiratory rate, and blood pressure) will be assessed.

    Time frame: Up to 28 weeks

  5. Part A: Number of Participants with Clinically Significant Change in 12-lead Electrocardiogram (ECG) Parameters

    Number of participants with clinically significant change in 12-lead ECG parameters will be assessed.

    Time frame: Up to 28 weeks

  6. Part B: Number of Participants with Clinically significant changes in laboratory values (haematology, chemistry and urinalysis)

    Number of Participants with clinically significant changes in laboratory values (haematology, chemistry and urinalysis) will be assessed.

    Time frame: Up to 42 weeks

  7. Part B: Number of Participants with Clinically Significant Change in vital signs

    Number of participants with clinically significant change in vital signs (tympanic temperature, pulse rate, respiratory rate, and blood pressure) up to end of intervention period will be assessed.

    Time frame: Up to 42 weeks

  8. Part B: Number of Participants with Clinically Significant Change in 12-lead Electrocardiogram (ECG) Parameters

    Number of participants with clinically significant change in 12-lead ECG parameters will be assessed.

    Time frame: Up to 42 weeks

Secondary outcomes

  1. Part A: Area Under the Concentration-time Curve to the Last Quantifiable Concentration [AUC(0-t)]

    Blood samples were collected at the indicated time points for pharmacokinetic (PK) analysis. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Up to 28 weeks

  2. Part A: Area Under the Concentration-time Curve to the Infinity (inf) [AUC(0-inf)]

    Blood samples were collected at the indicated time points for PK analysis. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Up to 28 weeks

  3. Part A: Maximum Concentration (Cmax)

    Blood samples were collected at the indicated time points for PK analysis. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Up to 28 weeks

  4. Part B: Area Under the Concentration-time Curve Over the Dosing Interval [AUC(0-tau)]

    Blood samples were collected at the indicated time points for PK analysis. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Up to 42 weeks

  5. Part B: Cmax

    Blood samples were collected at the indicated time points for PK analysis. PK parameters were calculated by standard non-compartmental analysis.

    Time frame: Up to 42 weeks

  6. Part A: Number of Participants with Anti-Drug Antibodies (ADA) against GSK3682995B

    Blood samples were analyzed for the presence of anti-GSK3682995B antibodies by binding ADA assay.

    Time frame: Up to 28 weeks

  7. Part B: Number of participants with Incidence of Anti-Drug Antibodies (ADA) against GSK3682995B

    Blood samples were analyzed for the presence of anti-GSK3682995B antibodies by binding ADA assay.

    Time frame: Up to 42 weeks

  8. Part A: Ratio to Baseline in Absolute and Relative Blood Eosinophil Count

    Ratio to baseline in absolute and relative blood eosinophil count will be assessed.

    Time frame: Baseline and up to 28 weeks

  9. Part B: Ratio to Baseline in Absolute and Relative Blood Eosinophil Count

    Ratio to baseline in absolute and relative blood eosinophil count will be assessed.

    Time frame: Baseline and up to 42 weeks

07

Study locations

31 sites
  • GSK Investigational Site
    Yuma, Arizona 85365, United States
  • GSK Investigational Site
    Hialeah, Florida 33016, United States
  • GSK Investigational Site
    Orange City, Florida 32763, United States
  • GSK Investigational Site
    Plantation, Florida 33324-7006, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Shelby, North Carolina 28150, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
  • GSK Investigational Site
    Austin, Texas 78744, United States
  • GSK Investigational Site
    Hanover, Lower Saxony 30159, Germany
  • GSK Investigational Site
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • GSK Investigational Site
    Ahrensburg, 22926, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 10119, Germany
  • GSK Investigational Site
    Berlin, 14050, Germany
  • GSK Investigational Site
    Dresden, 01069, Germany
  • GSK Investigational Site
    Frankfurt, 60596, Germany
  • GSK Investigational Site
    Hamburg, 20253, Germany
  • GSK Investigational Site
    Hamburg, Hamburg, Germany
  • GSK Investigational Site
    Leipzig, 04207, Germany
  • GSK Investigational Site
    Lübeck, 23552, Germany
  • GSK Investigational Site
    Mainz, 55128, Germany
  • GSK Investigational Site
    Blackpool, Lancashire FY2 0JH, United Kingdom
  • GSK Investigational Site
    Harrow, Middlesex HA1 3UJ, United Kingdom
  • GSK Investigational Site
    Barnsley, S75 3DL, United Kingdom
  • GSK Investigational Site
    Cambridge, CB2 0GG, United Kingdom
  • GSK Investigational Site
    Cannock, WS11 0BN, United Kingdom
  • GSK Investigational Site
    London, United Kingdom
  • GSK Investigational Site
    Manchester, M23 9QZ, United Kingdom
  • GSK Investigational Site
    West Yorkshire, LS10 1DU, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 36 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2023
First posted
Dec 4, 2023
StartActual
Nov 27, 2023
Primary completionEst.
Dec 16, 2026
CompletionEst.
Dec 16, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 5 sites removed
Show 4 added (2 Germany, 2 United Kingdom)
  • GSK Investigational Site · Hanover, Germany
  • GSK Investigational Site · Schwerin, Germany
  • GSK Investigational Site · Blackpool, United Kingdom
  • GSK Investigational Site · Harrow, United Kingdom
Show 5 removed
  • GSK Investigational Site · Hanover, Germany
  • GSK Investigational Site · Immenhausen, Germany
  • GSK Investigational Site · Schwerin, Germany
  • GSK Investigational Site · Blackpool, United Kingdom
  • GSK Investigational Site · London, United Kingdom
Nov 6, 2026
Primary completion
Dec 17, 2026→Dec 16, 2026
Nov 6, 2026
Study completion
Dec 17, 2026→Dec 16, 2026
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    4 sites added, 5 sites removed
    Show 4 added (2 Germany, 2 United Kingdom)
    • GSK Investigational Site · Hanover, Germany
    • GSK Investigational Site · Schwerin, Germany
    • GSK Investigational Site · Blackpool, United Kingdom
    • GSK Investigational Site · Harrow, United Kingdom
    Show 5 removed
    • GSK Investigational Site · Hanover, Germany
    • GSK Investigational Site · Immenhausen, Germany
    • GSK Investigational Site · Schwerin, Germany
    • GSK Investigational Site · Blackpool, United Kingdom
    • GSK Investigational Site · London, United Kingdom
    Primary completion Dec 17, 2026→Dec 16, 2026
    Study completion Dec 17, 2026→Dec 16, 2026
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06154837
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 4, 2023
Start date
Nov 27, 2023
Primary completion
Dec 16, 2026 (estimated)
Completion
Dec 16, 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK3862995B

Start the discussion